Fig. 8: Overview of pCHARME role in cardiomyocyte physiology and disease. | Nature Communications

Fig. 8: Overview of pCHARME role in cardiomyocyte physiology and disease.

From: LncRNA HSCHARME is altered in human cardiomyopathies and promotes stem cell-derived cardiomyogenesis via splicing regulation

Fig. 8: Overview of pCHARME role in cardiomyocyte physiology and disease.

Under physiological conditions (Physiology) pCHARME localizes within S35-containing domains and acts as a decoy for the splicing repressor PTBP1, thereby positively regulating the expression of genes involved in the differentiation of human cardiomyocytes. In DCM and HCM cardiomyopathy hearts (Pathology), pCHARME is aberrantly upregulated, and its target genes -many of which are associated with the diseases- are also dysregulated. This scenario envisages original therapeutic approaches (Therapy) aimed at regulating disease-linked genes through pCHARME modulation.

Back to article page